Literature DB >> 14603704

[External electrical cardioversion of atrial arrhythmia: predictive criteria of success].

O Paziaud1, O Piot, J Rousseau, X Copie, T Lavergne, L Guize, J Y Le Heuzey.   

Abstract

AIM: Supraventricular arrhythmia is a major public health problem because of its prevalence and clinical consequences. The first step of the treatment usually consists in restoring sinusal rhythm. The aim of this study is to evaluate results and predictive factors of success of electrical cardioversion.
METHODS: We studied a series of 143 consecutive electric cardioversion preformed in 131 French patients.
RESULTS: The rate of successful direct current cardioversion was 91.2%. Negative predictive factors are the height body mass index and the age of arrhythmia. Atrial flutter is a predictive factor of success. These results agree with published results. Our study highlights the interest of some nonantiarrhythmic drugs received by the patient during the period before the direct current cardioversion. Thus, a spironolactone treatment appears to be a new predictive factor of the success of electrical cardioversion (success in patients treated with spironolactone: 100% vs 89% without, P = 0.04).
CONCLUSIONS: Our results agree with usual predictive factors of the success of cardioversion. Nevertheless, a new approach is that of the positive effect of spironolactone on cardioversion. A prospective randomized study is necessary to confirm this result.

Entities:  

Mesh:

Year:  2003        PMID: 14603704     DOI: 10.1016/s0003-3928(03)00089-1

Source DB:  PubMed          Journal:  Ann Cardiol Angeiol (Paris)        ISSN: 0003-3928


  1 in total

1.  Effects of Mineralocorticoid Receptor Antagonists on Atrial Fibrillation Occurrence: A Systematic Review, Meta-Analysis, and Meta-Regression to Identify Modifying Factors.

Authors:  Joachim Alexandre; Charles Dolladille; Laurent Douesnel; Jonaz Font; Rafal Dabrowski; Linda Shavit; Damien Legallois; Christian Funck-Brentano; Laure Champ-Rigot; Pierre Ollitrault; Farzin Beygui; Theodora Bejan-Angoulvant; Jean-Jacques Parienti; Paul Milliez
Journal:  J Am Heart Assoc       Date:  2019-11-12       Impact factor: 5.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.